| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/27/2002 | CN1081460C Use of medicine for reducing tissue damage associated with non-cardiac ischemia by aldose reductase inhibitor |
| 03/26/2002 | US6362371 β2- adrenergic receptor agonists |
| 03/26/2002 | US6362336 Administering a quinazoline derivative to a warm-blooded animal for producing an antiangiogenic and/or vascular permeability reducing effect |
| 03/26/2002 | US6362324 Used as target for diagnosis and treatment in aminopeptidase-related disorders such as aging, cancers, cataracts, cystic fibrosis and leukemias; used in drug-screening to identify agonists, antagonists |
| 03/26/2002 | US6362316 Human metabotropic glutamate receptor subtype mGluR6 protein |
| 03/26/2002 | US6362237 Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| 03/26/2002 | US6362236 Statin compound |
| 03/26/2002 | US6362234 Water-soluble prodrugs of propofol for treatment of migrane |
| 03/26/2002 | US6362230 Alzheimer's disease |
| 03/26/2002 | US6362210 Carboxylic acid amides, pharmaceutical compositions containing these compounds and their use |
| 03/26/2002 | US6362209 Heterocyclic aromatic oxazole compounds and use thereof |
| 03/26/2002 | US6362199 Central nervous system disorders; psychological disorders |
| 03/26/2002 | US6362198 Anticholesterol, antilipemic agent |
| 03/26/2002 | US6362195 Inhibitor of nitric oxide synthase; central nervous system disorders |
| 03/26/2002 | US6362193 Antiinflammatory agents |
| 03/26/2002 | US6362190 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, n'-((1-(aminoiminomethyl)4-piperidinyl) methyl)-n-(3,3-diphenylpropionyl)-l-proline amide |
| 03/26/2002 | US6362182 Hypotensive agents; anticholesterol agents; benign prostatic hypertropic |
| 03/26/2002 | US6362180 Antagonist to corticotropin releasing factor |
| 03/26/2002 | US6362178 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| 03/26/2002 | US6362163 Administering polypeptide |
| 03/26/2002 | US6362161 Copolymer-1 improvements on compositions of copolymers |
| 03/26/2002 | US6361997 Genetically modified CD34-negative adherently growing stem cells and their use in gene therapy |
| 03/26/2002 | US6361967 Axor10, a g-protein coupled receptor |
| 03/26/2002 | US6361946 A bone marrow modulating method in mammals by adminstering a polypeptide that binds to at least one endothelial cell surface receptor to modulates myelopoiesis |
| 03/26/2002 | US6361938 Peptides which enhance transport across tissues and methods of identifying and using the same |
| 03/26/2002 | US6361797 Hydrogel compositions useful for the sustained release of macromolecules and methods of making same |
| 03/26/2002 | US6361776 Polypeptide isolated from mycobacterium vaccae comprising specified amino acid sequence, capable of eliciting and/or enhancing immune response to heterologous antigen |
| 03/26/2002 | US6361769 Stimulation of host defense mechanisms against viral challenges |
| 03/26/2002 | US6361768 Hydrophilic ampholytic polymer |
| 03/26/2002 | US6361760 Aerosol composition comprising tricyclic compound or pharmaceutically acceptable salt thereof, liquefied hydrofluoroalkane and medium-chain fatty acid triglyceride |
| 03/26/2002 | US6361758 Cosolvent formulations |
| 03/26/2002 | CA2180570C Isolated p27 protein and its encoding nucleic acid molecules |
| 03/26/2002 | CA2137551C A novel endothelial cell molecule mediating lymphocyte binding in man |
| 03/26/2002 | CA2094703C Substituted piperazines as central nervous system agents |
| 03/21/2002 | WO2002023199A2 Method, system, apparatus and device for discovering and preparing chemical compounds |
| 03/21/2002 | WO2002023184A1 Method for treatment of insulin resistance in obesity and diabetes |
| 03/21/2002 | WO2002022871A2 Polymorphic bone morphogenetic protein 2 |
| 03/21/2002 | WO2002022864A1 The method of detecting mutant dspp gene of hereditary opalescent |
| 03/21/2002 | WO2002022851A2 Novel tumor-associated marker |
| 03/21/2002 | WO2002022819A2 Calcium binding proteins |
| 03/21/2002 | WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses |
| 03/21/2002 | WO2002022678A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/21/2002 | WO2002022677A2 Variants of allergenic proteins of the group 2 of dermatophagoides |
| 03/21/2002 | WO2002022655A1 Glutathione conjugates with distamycin derivatives having antitumoral activity |
| 03/21/2002 | WO2002022635A1 Antisense modulation of clusterin expression |
| 03/21/2002 | WO2002022630A1 Purine derivatives |
| 03/21/2002 | WO2002022621A2 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 03/21/2002 | WO2002022620A2 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f2$g(a) antagonists |
| 03/21/2002 | WO2002022615A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022611A2 Caspase inhibitors and uses thereof |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022609A1 Process for producing paroxetine salt containing substantially no organic solvent |
| 03/21/2002 | WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022602A2 Triazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022600A2 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | WO2002022599A2 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | WO2002022598A1 Quinolinone derivatives as tyrosine kinase inhibitors |
| 03/21/2002 | WO2002022597A1 N-phenyl-2-pyrimidine-amine derivatives |
| 03/21/2002 | WO2002022595A1 N-substituted benzothiophenesulfonamide derivatives |
| 03/21/2002 | WO2002022592A2 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | WO2002022588A1 Novel pyrimidine derivative and novel pyridine derivative |
| 03/21/2002 | WO2002022581A1 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 03/21/2002 | WO2002022577A2 Hydroxamate derivatives useful as deacetylase inhibitors |
| 03/21/2002 | WO2002022576A2 3-substituted indole carbohydrazides useful as cell proliferation and angiogenesis inhibitors |
| 03/21/2002 | WO2002022575A1 Amidine inhibitors of serine proteases |
| 03/21/2002 | WO2002022574A1 Tricyclic heterocyclic compound, process for producing the same, and use thereof |
| 03/21/2002 | WO2002022572A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | WO2002022562A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022557A2 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022171A2 Pharmaceutical composition having specific water activity |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022161A2 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | WO2002022160A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | WO2002022142A1 Cough depressant composition containing iron for angiotensin-converting enzyme inhibitor inducing cough |
| 03/21/2002 | WO2002022140A1 Homeostasis-maintaining agents |
| 03/21/2002 | WO2002022135A1 Creatine ester pronutrient compounds and formulations |
| 03/21/2002 | WO2002022134A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | WO2002022129A1 A method of analgesia |
| 03/21/2002 | WO2002022123A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022114A2 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/21/2002 | WO2002022108A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 03/21/2002 | WO2001096388A8 Compositions and methods for the therapy and diagnosis of colon cancer |
| 03/21/2002 | WO2001093843A3 Benzoic acid esters having antiplasmid effect |
| 03/21/2002 | WO2001087846A3 Tricyclic pyrazole derivatives as protein kinase inhibitors |
| 03/21/2002 | WO2001087039A3 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2 |
| 03/21/2002 | WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/21/2002 | WO2001078703A3 Methods and compositions for modulating alpha adrenergic receptor activity |
| 03/21/2002 | WO2001078702A3 Methods and compositions for modulating alpha adrenergic receptor activity |
| 03/21/2002 | WO2001074365A3 An efficacious dosage regimen of galantamine that reduces side effects |
| 03/21/2002 | WO2001072841A3 Isolated human g-protein coupled receptors that are members of the aminergic subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |